

Audit Review Table					
Molina Healthcare of New Mexico (Org ID: 955, Sub ID: 16749, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)					
Measurement Year - 2025; Date & Timestamp - 6/2/2026 3:47:35 PM					
This submission is on the stage: Submission Finalized					
Measure/Data Element	Benefit Offered	Rate	Status	Audit Designation	Comment
Effectiveness of Care					
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)					
BMI percentile (Total)		84.18%	R	R	Reported
Counseling for Nutrition (Total)		72.51%	R	R	Reported
Counseling for Physical Activity (Total)		69.83%	R	R	Reported
Lead Screening in Children (LSC)					
Lead Screening in Children		53.68%	R	R	Reported
Chlamydia Screening (CHL)					
(Total)		52.63%	R	R	Reported
Oral Evaluation, Dental Services (OED)	Y				
(0-2)		25.71%	R	R	Reported
(3-5)		53.42%	R	R	Reported
(6-14)		62.30%	R	R	Reported
(15-20)		43.91%	R	R	Reported
(Total)		50.22%	R	R	Reported
Topical Fluoride for Children (TFC)					
(1-2)		9.30%	R	R	Reported
(3-4)		13.50%	R	R	Reported
(Total)		11.36%	R	R	Reported
Appropriate Testing for Pharyngitis (CWP)	Y				
(Total)		79.38%	R	R	Reported
Pharmacotherapy Management of COPD Exacerbation (PCE)	Y				
Systemic Corticosteroid		71.43%	R	R	Reported
Bronchodilator		77.78%	R	R	Reported
Asthma Medication Ratio (AMR)	Y				
(Total)			NA	R	Reported
Controlling High Blood Pressure (CBP)					
Controlling High Blood Pressure		68.13%	R	R	Reported
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)	Y				
Persistence of Beta-Blocker Treatment After a Heart Attack		54.55%	NA	R	Reported
Statin Therapy for Patients With Cardiovascular Disease (SPC)	Y				
Received Statin Therapy (Total)			NA	R	Reported
Statin Adherence 80% (Total)			NA	R	Reported
Cardiac Rehabilitation (CRE)					
Initiation (Total)		10.00%	R	R	Reported
Engagement1 (Total)		0.00%	R	R	Reported
Engagement2 (Total)		0.00%	R	R	Reported
Achievement (Total)		0.00%	R	R	Reported
Glycemic Status Assessment for Patients With Diabetes (GSD)					
Glycemic Status <8.0%		49.39%	R	R	Reported
Glycemic Status >9.0%		43.80%	R	R	Reported
Blood Pressure Control for Patients With Diabetes (BPD)					
Blood Pressure Control for Patients With Diabetes		67.15%	R	R	Reported
Eye Exam for Patients With Diabetes (EED)					
Eye Exam for Patients With Diabetes		34.82%	R	R	Reported
Kidney Health Evaluation for Patients With Diabetes (KED)					
(Total)		37.14%	R	R	Reported
Statin Therapy for Patients With Diabetes (SPD)	Y				
Received Statin Therapy		85.71%	NA	R	Reported
Statin Adherence 80%		75.00%	NA	R	Reported
Diagnosed Mental Health Disorders (DMH)					
(Total)		24.68%	R	R	Reported
Follow-Up After Hospitalization for Mental Illness (FUH)	Y				
30 days (Total)		58.86%	R	R	Reported
7 days (Total)		40.35%	R	R	Reported
Follow-Up After Emergency Department Visit for Mental Illness (FUM)	Y				
30 days (Total)		47.60%	R	R	Reported
7 days (Total)		30.05%	R	R	Reported
Diagnosed Substance Use Disorders (DSU)					
Alcohol (Total)		4.94%	R	R	Reported
Opioid (Total)		4.71%	R	R	Reported
Other (Total)		7.10%	R	R	Reported
Any (Total)		12.07%	R	R	Reported
Follow-Up After High-Intensity Care for Substance Use Disorder (FUI)	Y				

30 days (Total)		53.05%	R	R	Reported
7 Days (Total)		31.10%	R	R	Reported
Follow-Up After Emergency Department Visit for Substance Use (FUA)	Y				
30 days (Total)		41.61%	R	R	Reported
7 days (Total)		27.29%	R	R	Reported
Pharmacotherapy for Opioid Use Disorder (POD)	Y				
(Total)		19.35%	R	R	Reported
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)	Y				
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications		77.34%	R	R	Reported
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)					
Diabetes Monitoring for People With Diabetes and Schizophrenia		60.00%	R	R	Reported
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)					
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia			NA	R	Reported
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	Y				
Adherence to Antipsychotic Medications for Individuals With Schizophrenia		54.17%	R	R	Reported
Appropriate Treatment for Upper Respiratory Infection (URI)	Y				
(Total)		81.73%	R	R	Reported
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)	Y				
(Total)		51.94%	R	R	Reported
Use of Imaging Studies for Low Back Pain (LBP)					
(Total)		63.59%	R	R	Reported
Use of Opioids at High Dosage (HDO)	Y				
Use of Opioids at High Dosage		1.29%	R	R	Reported
Use of Opioids From Multiple Providers (UOP)	Y				
Multiple Prescribers		18.98%	R	R	Reported
Multiple Pharmacies		2.92%	R	R	Reported
Multiple Prescribers and Multiple Pharmacies		2.55%	R	R	Reported
Risk of Continued Opioid Use (COU)	Y				
>=15 Days (Total)		3.40%	R	R	Reported
>=31 Days (Total)		2.62%	R	R	Reported
Access/Availability of Care					
Adults' Access to Preventive/Ambulatory Health Services (AAP)					
(Total)		66.36%	R	R	Reported
Initiation and Engagement of Substance Use Disorder Treatment (IET)	Y				
Initiation of SUD Treatment - Total (Total)		47.81%	R	R	Reported
Engagement of SUD Treatment - Total (Total)		16.75%	R	R	Reported
Prenatal and Postpartum Care (PPC)					
Timeliness of Prenatal Care		79.56%	R	R	Reported
Postpartum Care		75.43%	R	R	Reported
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)	Y				
(Total)		51.72%	NA	R	Reported
Utilization and Risk Adjusted Utilization					
Well-Child Visits in the First 30 Months of Life (W30)					
(First 15 Months)		61.43%	R	R	Reported
(15 Months-30 Months)		62.34%	R	R	Reported
Child and Adolescent Well-Care Visits (WCV)					
(Total)		50.85%	R	R	Reported
Antibiotic Utilization for Respiratory Conditions (AXR)	Y				
(Total)		28.80%	R	R	Reported
Plan All-Cause Readmissions (PCR)			R	R	Reported
Acute Hospital Utilization (AHU)			R	R	Reported
Health Plan Descriptive Information					
Enrollment by Product Line (ENP)			R	R	Reported
Language Diversity of Membership (LDM)			R	R	Reported
Race/Ethnicity Diversity of Membership (RDM)			R	R	Reported
Measures Reported Using Electronic Clinical Data Systems					
Childhood Immunization Status (CIS-E)					
DTaP		61.85%	R	R	Reported
IPV		78.75%	R	R	Reported
MMR		79.29%	R	R	Reported
HIB		77.93%	R	R	Reported
Hepatitis B		79.02%	R	R	Reported
VZV		77.38%	R	R	Reported
Pneumococcal Conjugate		58.86%	R	R	Reported

Hepatitis A		77.66%	R	R	Reported
Rotavirus		61.31%	R	R	Reported
Influenza		23.71%	R	R	Reported
Combo 3		52.04%	R	R	Reported
Combo 7		44.96%	R	R	Reported
Combo 10		17.44%	R	R	Reported
Immunizations for Adolescents (IMA-E)					
Meningococcal		80.92%	R	R	Reported
Tdap		82.15%	R	R	Reported
HPV		35.08%	R	R	Reported
Combination 1		80.62%	R	R	Reported
Combination 2		34.77%	R	R	Reported
Breast Cancer Screening (BCS-E)					
(Total)		66.67%	NA	R	Reported
Documented Assessment After Mammogram (DBM-E)					
Documented Assessment After Mammogram		0.00%	R	R	Reported
Follow-Up After Abnormal Mammogram Assessment (FMA-E)					
Follow-Up After Abnormal Mammogram Assessment			NA	R	Reported
Cervical Cancer Screening (CCS-E)					
Cervical Cancer Screening		26.30%	R	R	Reported
Colorectal Cancer Screening (COL-E)					
(Total)		53.85%	R	R	Reported
Blood Pressure Control for Patients With Hypertension (BPC-E)					
Blood Pressure Control for Patients With Hypertension		33.25%	R	R	Reported
Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)	Y				
Initiation Phase		50.00%	R	R	Reported
Continuation and Maintenance Phase		62.50%	NA	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)	Y				
Blood Glucose Testing (Total)		62.92%	R	R	Reported
Cholesterol Testing (Total)		33.71%	R	R	Reported
Blood Glucose and Cholesterol Testing (Total)		33.71%	R	R	Reported
Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)					
Depression Screening (Total)		7.87%	R	R	Reported
Follow-Up on Positive Screen (Total)		65.22%	R	R	Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)					
Utilization of PHQ-9-Total (Total)		7.46%	R	R	Reported
Depression Remission or Response for Adolescents and Adults (DRR-E)					
Follow-Up PHQ-9 (Total)			NA	R	Reported
Depression Remission (Total)			NA	R	Reported
Depression Response (Total)			NA	R	Reported
Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)					
Unhealthy Alcohol Use Screening (Total)		0.00%	R	R	Reported
Alcohol Counseling or Other Follow-Up Care (Total)			NA	R	Reported
Adult Immunization Status (AIS-E)					
Influenza (Total)		11.61%	R	R	Reported
Td/Tdap (Total)		40.50%	R	R	Reported
Zoster (Total)		10.99%	R	R	Reported
Hepatitis B (Total)		17.78%	R	R	Reported
Pneumococcal (65+)		38.00%	R	R	Reported
Prenatal Immunization Status (PRS-E)					
Influenza		27.27%	R	R	Reported
Tdap		62.89%	R	R	Reported
Combination		24.30%	R	R	Reported
Prenatal Depression Screening and Follow-Up (PND-E)					
Depression Screening		6.86%	R	R	Reported
Follow-Up on Positive Screen		0.00%	NA	R	Reported
Postpartum Depression Screening and Follow-Up (PDS-E)					
Depression Screening		7.08%	R	R	Reported
Follow-Up on Positive Screen		100.00%	NA	R	Reported
Social Need Screening and Intervention (SNS-E)					
Food Screening (Total)		0.00%	R	R	Reported
Food Intervention (Total)		0.00%	NA	R	Reported
Housing Screening (Total)		0.00%	R	R	Reported
Housing Intervention (Total)		0.00%	NA	R	Reported
Transportation Screening (Total)		0.00%	R	R	Reported
Transportation Intervention (Total)		0.00%	NA	R	Reported